TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04287413

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physiotherapist-led primary care model for back pain
Description: Assessment and screening: taking a history; screening for red flags, comorbidities, and risk factors of ongoing pain and disability; physical examination.~Brief individualized intervention at the first visit: effective communication, cognitive reassurance, a few exercises, and advice/strategies to stay active.~Health services navigation: PT assistance with navigating healthcare services based on the assessment findings. First, red-flags requiring emergency or urgent referrals. Next, comorbid conditions that would benefit from care from other healthcare providers. Finally, referral to PT (if appropriate).~Providing additional physiotherapy care to people with an unmet need: Additional physiotherapy care will be provided to patients who have an identified need for physiotherapy but no physiotherapy coverage through private or government health insurance plans.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: The physician led primary care intervention will be unstandardized to best reflect standard clinical practice in Canada.
Study: NCT04629248

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Open Label: An intravenous (IV) infusion of 1000 milligram (mg) of obinutuzumab will be administered at Week 0, Week 2, Week 24, and Week 26. Participants who relapse during the open-label treatment period may be eligible for further treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Open Label: Participants will receive tacrolimus at a starting oral dose (PO) of 0.05 mg/kilogram (kg) (participant dry weight) per day divided into two equal doses given at 12-hour intervals, titrated to serum trough level 5-7 Nanograms per millilitre (ng/mL). Optimized tacrolimus dose will be maintained for a maximum 52 weeks dependent on response and then tapered over 8 weeks. Participants who relapse during the open-label treatment period will have their dose of tacrolimus tapered over 8 weeks and may be eligible for further treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Premedication: Methylprednisolone 80 mg IV will be administered between 30 and 60 minutes prior to the obinutuzumab infusion in all study periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Premedication: Acetaminophen (650-1000 mg, or equivalent dose of a similar agent) PO or IV will be administered between 30 and 60 minutes prior to the obinutuzumab infusion in all study periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Description: Premedication: Diphenhydramine (50 mg, or equivalent dose of a similar agent) PO or IV will be administered between 30 and 60 minutes prior to the obinutuzumab infusion in all study periods.
Study: NCT04924075

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belzutifan
Description: Belzutifan, 120 mg, oral, once daily (QD) until progressive disease or discontinuation.
Study: NCT05580861

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfasalazine
Description: Sulfazalazine 500mg-tablets ; 7 dose levels explored in the phase I part of the trial.
Study: NCT05790954

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Guided imagery
Description: Three days before the cesarean section, the participants will be given a guided imagery audio recording and will be asked to listen to it before going to bed every evening until the day of the cesarean section. On the morning of the cesarean section, after the patient is prepared, the guided imagery audio recording will be played again.
Study: NCT05673252

Intervention type: DIAGNOSTIC_TEST
Intervention: Venous blood sample
Description: Blood chemistry tests: neutrophil;lymphocyte; monocyte; platelet counts

Intervention type: PROCEDURE
Intervention: biopsy
Description: histopathology findings
Study: NCT05960695

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stretching
Description: Among the stretching exercises, iliopsoas, adductor, and hamstring stretches will be taught. Participants will repeat the stretches 3 times a week with 3 repetitions of each stretch for 20 seconds. The exercises will be done online by the physiotherapist.~The experimental group will be given both stretching and relaxation exercises. The Control group will be given only stretching exercises.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stretching
Description: Among the stretching exercises, iliopsoas, adductor, and hamstring stretches will be taught. Participants will repeat the stretches 3 times a week with 3 repetitions of each stretch for 20 seconds. The exercises will be done online by the physiotherapist.~The experimental group will be given both stretching and relaxation exercises. The Control group will be given only stretching exercises.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Relaxation
Description: Diaphragmatic breathing will be taught as a relaxation exercise. The experimental group will be given both stretching and relaxation exercises. The Control group will be given only stretching exercises.
Study: NCT05118581

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ultrasound guided vascular access
Description: Arterial or venous catheterization guided by ultrasound
Study: NCT06553209

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CM512
Description: CM512 injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CM512
Description: CM512 injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CM512
Description: CM512 injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CM512
Description: CM512 injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CM512
Description: CM512 injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CM512
Description: CM512 injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CM512
Description: CM512 injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study: NCT04873284

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fosaprepitant
Description: Granisetron+dexamethasone: granisetron:40mcg/kg, IV ; dexamethasone : S\<0.6m2, 2 mg/dose, q12h IV/PO; S\>0.6m2, 4 mg/dose, q12h , IV/PO. When used with fosaprepitant, dexamethasone dose was halved.~Fosaprepitant: 4 mg/kg IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aprepitant
Description: Granisetron+dexamethasone: granisetron:40mcg/kg, IV ; dexamethasone : S\<0.6m2, 2 mg/dose, q12h IV/PO; S\>0.6m2, 4 mg/dose, q12h , IV/PO. When used with aprepitant, dexamethasone dose was halved.~Oral aprepitant: D1：Powder for suspension 3.0 mg/kg (up to 125 mg),D2，D3：Powder for suspension 2.0 mg/kg (up to 80 mg).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granisetron plus dexamethasone
Description: Granisetron+dexamethasone: granisetron:40mcg/kg, IV ; dexamethasone : S\<0.6m2, 2 mg/dose, q12h IV/PO; S\>0.6m2, 4 mg/dose, q12h , IV/PO.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granisetron plus dexamethasone
Description: Granisetron+dexamethasone: granisetron:40mcg/kg, IV ; dexamethasone : S\<0.6m2, 2 mg/dose, q12h IV/PO; S\>0.6m2, 4 mg/dose, q12h , IV/PO.
Study: NCT05444478

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Microwave ablation
Description: only microwave ablation for tumor

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Microwave ablation
Description: only microwave ablation for tumor
Study: NCT06553209

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study: NCT05444478

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: lenvatinib (80 mg for body no more than 60kg，120 mg for body weight \>60 kg)
Study: NCT05874453

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: eye care protocol
Description: The lower conjunctiva of the eye to be treated is opened, 1-2 drops of gel are applied, the eye is closed. Cleaning eye secretions is done with sterile distilled water. A gel containing trehalose, hyaluronic acid and carbomer will be applied every 2-4 hours in accordance with intensive care eye care protocol. In order to determine the exposure keratopathy, staining with Fluorescein Sodium will be performed by the ophthalmologist on days 0, 5 and 10, and a blue light pen will be used for evaluation. In order to determine the degree of dry eye, the Schirmer I test will be performed on the 0th and 10th days
Study: NCT06152250

Intervention type: OTHER
Group type: OTHER
Intervention: Liver Fine-Needle Aspiration
Description: At the time of inclusion, when liver biopsy will be performed as part of routine medical management, fine-needle aspiration will also be made in all patients.~The procedure will be performed in the Day Hospital, immediately after the liver biopsy.
Study: NCT06020508

Intervention type: DEVICE
Intervention: Group 1 - Lumoptik BrightPoint Epidural Device
Description: Participants will undergo a neuraxial procedure to measure loss of resistance with saline in conjunction with the Lumoptik BrightPoint Epidural Device.
Study: NCT04731376

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive standard peri-operative care

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT06193317

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transauricular vagus nerve stimulation (taVNS)
Description: Transauricular vagus nerve stimulation (taVNS) is a simple technique in which small surface electrodes are placed over the skin of the ear that are thought to be innervated by the auricular branch of the vagus nerve (ABVN).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transauricular vagus nerve stimulation (taVNS)
Description: Transauricular vagus nerve stimulation (taVNS) is a simple technique in which small surface electrodes are placed over the skin of the ear that are thought to be innervated by the auricular branch of the vagus nerve (ABVN).
Study: NCT05329506

Intervention type: OTHER
Intervention: patient population
Description: questionnaires, standard of care
Study: NCT06366945

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin AUC 5 on weeks 1, 3, and 6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Tislelizumab 200 mg on weeks 3, 6, and 9;if adjuvant immunotherapy is omitted, Tislelizumab will be administered on weeks 1, 3, 6, 9, 12, 15 after surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polymeric Micellar Paclitaxel
Description: Polymeric Micellar Paclitaxel 300mg/mg/m2 on weeks 1, 3 and 6
Study: NCT04731376

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies; Quality of life questionnaires will be given both preoperatively and at 3-months postoperatively
Study: NCT06366945

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical Resection of Primary +/- Neck Dissection
Description: Twenty-eight days (+ 7 days) following the 3rd cycle of neoadjuvant therapy, patients will then undergo definitive surgical resection of the primary site +/- neck dissection(s).

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Post-operative radiation therapy
Description: Post-operative radiation therapy +/- radiosensitizing agent(s) will be administered per standard-of-care based on pathologic staging of the surgical specimen. If there is an excellent response to treatment with a high degree of downstaging the addition of adjuvant radiation may be omitted if NCCN guidelines are met. If the pathologic assesment following induction systemic therapy and surgery is ypT(pCR 或 MPR) and ypN(pCR) or ypT（ pCR 或 MPR）and ypN（ MPR）without the presence of Serious Adverse Event, adjuvant radiation will not be administered. Otherwise, patients will receive adjuvant RT-based treatment with standard radiation techniques.
Study: NCT05553782

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Implantable Microdevice (IMD)
Description: * Percutaneous CT image-guided placement of the microdevice(s). At least one, and up to 3, devices will be placed in each tumor.~* Drugs will be released from the microdevice into local tumor tissues. The duration of drug release will be for a period of 3-5 days while the microdevice is in the tumor prior to retrieval. The local tissue is retrieved along with the microdevice and no residual drug will remain.~* Each microdevice harbors up to 20 drugs and/or drug combinations relevant to the treatment of salivary cancer. The drugs used will include some standard agents approved by the Food and Drug Administration (FDA) for treatment of different types of cancers, or drugs classes under investigational.~  * Drugs may include all or a subset of the following which each may be tested as single agents or in any number of combinations: Lenvatinib, Axitinib, All trans retinoic acid (ATRA), Venetoclax, Pembrolizumab, Cisplatin, Carboplatin, Vinorelbine
Study: NCT05618145

Intervention type: OTHER
Intervention: Clinical information
Description: The investigators will recruit PSC patients and collect important clinical information and laboratory investigation, together with biological samples.
Study: NCT04531670

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iRaPID
Description: Participants randomized to the iRaPID program will receive: a) same-day access to PrEP and OAT and educational counseling by the APN; b) safety-check phone calls/SMS; c) follow-up phone call/SMS; and d) clinical visit at Day 30

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: PWID participants randomized to the training as usual (TAU) will follow the existing clinical guidelines to receive PrEP, OAT, or both.
Study: NCT05260112

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ERICA
Description: Over 6 weeks, participants receive evidence-based video learning modules twice a week via a secure and HIPAA-compliant text messaging platform. These modules include: patient education on interstitial cystitis, bladder training, trial of an elimination diet, pelvic floor physical therapy including at-home myofascial trigger point release, guided mindfulness practice, and cognitive behavioral therapy for chronic pain.~At the end of each week, participants receive a check-in message. They also have the opportunity to text questions and concerns, which will be answered using an algorithm-based, clinically validated responses.
Study: NCT06454175

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: immunization schedule：Month 0，Month 2，Month 6

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 15-valent recombinant human papillomavirus vaccine (Hansenulapolymorpha)
Description: immunization schedule：Month 0，Month 2，Month 6
Study: NCT06069102

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: The usual care group will be given anti-hypertensive medications (i.e. beta blocker, calcium channel blocker, etc) if a subject's BP consistently exceeds 150/100 mmHg consistently.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tight blood pressure control
Description: The intervention group will be initiated on blood pressure medications (i.e. beta blocker, calcium channel blocker, etc) if a subject's hospital BP consistently exceeds 140/90 mmHg or home BP consistently exceeds 135/85 mmHg.
Study: NCT04362826

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Novel probiotic
Description: Investigational novel probiotic

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for probiotic
Study: NCT06497556

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Divarasib
Description: Divarasib will be administered orally QD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sotorasib
Description: Sotorasib will be administered orally QD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adagrasib
Description: Adagrasib will be administred orally BID
Study: NCT06301412

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: hypothermia
Description: hypothermia is started after intubation for endovascular treatment and induced by transnasal cooling (RhinoChill) to a target temperature of 35°C and hypothermia is then maintained at 35°C for 6 hours after recanalisation by surface cooling followed by slow rewarming by 0.2°C per hour to 36.5°C
Study: NCT04731376

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies; Quality of life questionnaires will be given both preoperatively and at 3-months postoperatively
Study: NCT06203639

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: UR Caregiver
Description: The UR Caregiver app was informed by previous research and developed in collaboration with caregiver partners. The app utilizes cognitive behavioural principles and is consistent with models of stress and coping. The app consists of seven modules. The app is available on IOS and Googe Play store. In addition to the didactic information provided in the app, worksheets are available in each module to practice the strategy/skill provided.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CLEAR Dementia Care
Description: A subset of participants will be randomly assigned to use the CLEAR Dementia Care app as part of an active control group. The app consists of features that primarily address care-related needs (as opposed to stress management strategies) allowing for a comparison with the UR Caregiver app. The app was developed by the Northern Health and Social Care Trust (Northern Ireland) and is freely available on both IOS and Google Play stores. The CLEAR Dementia Care app provides users with information about dementia (e.g., the different types of dementia, how dementia affects the brain, and symptoms associated with dementia). The app offers suggestions and alternative approaches to various care-related situations through illustrations/images that caregivers may experience.
Study: NCT04731376

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone Cypionate
Description: Given IM
Study: NCT05662241

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obexelimab
Description: Obexelimab is a monoclonal antibody that simultaneously binds CD19 and FcγRIIb, resulting in down regulation of B cell activity.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05094921

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aquatic Halliwick method
Description: The Halliwick Concept is a detailed swimming programme based on the scientific principles of body mechanics and the properties of water intended to educate individuals with special needs to be water safe and to move independently in the water as much as possible (Lambeck \& Stanat 2001a).The programme consists of 10 specific progressive stages that are achieved without the use of floatation devices (Lambeck \& Stanat 2001b).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional physical therapy
Description: Conventional selected exercise program for 60 minutes ,3 session per week for 3 successive months aiming to improve the motor functions of the children in form of: (1) Neuro-developmental technique, (2) Back and abdominal exercises to improve postural control and correct spinal deformities (3) improving postural responses, (4) Flexibility exercises of the soft tissue (5) Strengthening exercise (particularly knee extensors, hip abductors and the ankle dorsi-flexors muscles and (6) Improving standing, weight transfer and shift and finally facilitation of normal walking pattern .
Study: NCT04777721

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCG Danish
Description: BCG Danish 1331 is on the WHO list of pre-qualified vaccines and has a well-defined side effect profile. BCG is licensed for delivery via the intradermal route. It is not licensed for delivery via the aerosol route.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCG Danish
Description: BCG Danish 1331 is on the WHO list of pre-qualified vaccines and has a well-defined side effect profile. BCG is licensed for delivery via the intradermal route. It is not licensed for delivery via the aerosol route.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCG Danish
Description: BCG Danish 1331 is on the WHO list of pre-qualified vaccines and has a well-defined side effect profile. BCG is licensed for delivery via the intradermal route. It is not licensed for delivery via the aerosol route.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCG Danish
Description: BCG Danish 1331 is on the WHO list of pre-qualified vaccines and has a well-defined side effect profile. BCG is licensed for delivery via the intradermal route. It is not licensed for delivery via the aerosol route.
Study: NCT05463042

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intermittent Hypoxia
Description: During the intermittent hypoxia session, participants will be sitting during the entire breathing protocol. Hypoxic air will be inhaled through a mask connected to a two-way non-rebreathing valve, which will itself be connected to a 5-liter non-diffusing gas bag (Hans Rudolph, Inc, USA). The rebreathing bag will be connected to a certified medical grade gas tank containing 11% oxygen and a balance of nitrogen. The intermittent hypoxia protocol will consist of eight 4-min cycles of breathing hypoxic air interspersed with normoxic cycles breathing room air. After four min of hypoxia, participants will be switched back to breathing room air until resaturation, which takes approximately one minute. Once arterial oxygen saturation reaches baseline levels, participants will be switched back to breathing hypoxic air, beginning the next hypoxic cycle.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Normoxia (sham)
Description: During the sham condition, compressed air (21% oxygen) from a gas tank will be delivered throughout the protocol instead of 11% oxygen. Participants will not receive information about which condition (Intermittent hypoxia or sham) they are experiencing during the trials.
Study: NCT05315232

Intervention type: OTHER
Intervention: survey and interview
Description: qualitative assessment

Intervention type: OTHER
Intervention: survey and interview
Description: qualitative assessment
Study: NCT05941351

Intervention type: PROCEDURE
Group type: OTHER
Intervention: flap fixation
Description: flap fixation using running or interrupted sutures

Intervention type: PROCEDURE
Group type: OTHER
Intervention: flap fixation
Description: flap fixation using running or interrupted sutures